UNSPSC 51351520: Algestone acetophenide

This classification denotes a therapeutic progestin with the molecular formula C29H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OL7KC2O3OT, chemically known as 16alpha,17-((r)-1-phenylethylidendioxy-4-pregnen-3,20-dion but more generally known as algestone acetophenide, which bears US NIH Compound Identifier 32327. European Medicines Agency schedules Algestone acetophenide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12773MIG.

UNSPSC 51351520 Algestone acetophenide is a Commodity code for a specific pharmaceutical active ingredient supplied through cooperative purchasing agreements and multistate procurement alliances to state and local government health facilities, including hospitals, clinics, and correctional institutions. State and local governments acquire this product as part of broader generic pharmaceuticals procurement initiatives, typically bundled with other multi-source generics and OTC products under framework agreements with authorized drug wholesalers. The primary issuing bodies are state health departments and multistate cooperative purchasing organizations administering procurement on behalf of multiple member jurisdictions — counties, cities, school districts, and other local health agencies. Individual vendors responding to these opportunities must maintain cGMP certification and DSCSA compliance, supply through designated authorized wholesalers, and meet detailed product specification requirements including NDC codes, packaging configurations, and expiration-date thresholds.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. The solicitation covers participating state and local government facilities across Minnesota, Oregon, and other MMCAP member jurisdictions. Awarded vendors must supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of them with chargeback systems in place, and agree to a 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026, with contracts effective July 1, 2026 for an initial two-year term with optional extensions. Pricing competitiveness carries 75 percent evaluation weight, with the remaining points distributed across fixed pricing, EDI capability, administrative compliance, and fee agreement. Vendors must carry $5 million commercial general liability insurance and demonstrate price-quote flexibility through formats including flat price, net pricing, or WAC-minus structures.